nucleic acid amplification test quantitation as predictor

<1125> NUCLEIC ACID-BASED TECHNIQUES-GENERAL

These analytical procedures require a minimum quantity of nucleic acid, typically in the nanogram to microgram range. However, in the vast majority of cases, e.g., in the detection of viruses or rare cellular RNA species, the nucleic acid under assay is present in minute quantities (in the picogram to femtogram range), and an amplification step must be performed before the nucleic acid can be (PDF) Nucleic Acid Amplification-Alternative Methods of P olymerase chain reaction (PCR) was the first. nucleic acid amplification method developed and until. now has been the method of choice since its invention. by Mullis. [1] PCR is the preferr ed

Aptima HBV Quant assay package insert

The Aptima HBV Quant assay is an in vitro nucleic acid amplification test for the quantitation of hepatitis B virus (HBV) DNA in human plasma and serum on the fully automated Panther® system. Plasma may be prepared in ethylenediaminetetraacetic acid (EDTA), anticoagulant citrate dextrose (ACD) solution, and plasma preparation tubes (PPTs). CA2772770A1 - Improved nucleic acid quantitation method The present invention relates to methods of quantifying nucleic acids and in particular to an improved universal method of quantifying nucleic acids for gene eion studies without the need for normalising data to a housekeeping gene or to a synthetic gene of interest. CA2772770A1 - Improved nucleic acid quantitation method - Google COBAS® TaqMan® HCV Test v2 - DiagnosticsThe COBAS ® TaqMan ® HCV Test, v2.0 For Use With The High Pure System (HPS) is an in vitro nucleic acid amplification test for the quantitation of HCV RNA genotypes 1 through 6 in human serum or plasma, using the High Pure System Viral Nucleic Acid Kit for manual specimen preparation and the COBAS ® TaqMan ® 48 Analyzer for automated amplification and detection.

Diagnostics based on nucleic acid sequence variant

Oct 01, 2016 · In ISH, the nucleic acids to be imaged are first fixed to the protein matrix of the cells, typically using formaldehyde (a.k.a. formalin) or methanol, to prevent diffusion . Subsequently, DNA or RNA oligonucleotide probes are introduced and allowed to hybridize to the fixed target nucleic acids; unbound probes are washed away. Hepatitis C virus RNAThe COBAS AmpliPrep/COBAS TaqMan HCV Test is a nucleic acid amplification test for the quantitation of HCV RNA in human serum or plasma. Specimen preparation is automated using the COBAS AmpliPrep Instrument with amplification and detection automated using the COBAS TaqMan Updated Guidelines for the Use of Nucleic Acid

  • BackgroundUpdated RecommendationRevised Testing and Interpretation AlgorithmCautionsConventional tests for laboratory confirmation of TB include acid-fast bacilli (AFB) smear microscopy, which can produce results in 24 hours, and culture, which requires 2--6 weeks to produce results (5,6). Although rapid and inexpensive, AFB smear microscopy is limited by its poor sensitivity (45%--80% with culture-confirmed pulmonary TB cases) and its poor positive predictive value (50%--80%) for TB in settings in which nontuberculous mycobacteria are commonly isolated (3,6,7). NAA tests can provide reEvaluation of two, commercial, multi-dye, nucleic acid BACKGROUND:The cobas TaqScreen MPX Test, version 2.0, a multiplex, multi-dye nucleic acid amplification technology (NAT) test from Roche was evaluated by two European Blood Banks, the German Red Cross Blood Donor Service, Frankfurt, Germany and Centro de Hemoterapia y Hemodonación de Castilla y León, Valladolid, Spain.

    cobas HBV - Food and Drug Administration

    cobas® HBV is an in vitro nucleic acid amplification test for the quantitation of hepatitis B virus (HBV) DNA in human EDTA plasma or serum of HBV-infected individuals. This test is intended forTechniques for the evaluation of nucleic acid Accurate HIV-1 RNA quantitation with nucleic acid amplification assays (NAAA) is partly dependent on overall assay design to ensure proper and reproducible functioning in the presence of endogenous interfering substances present in a clinical specimen, or exogenous interfering substances introduced as a result of specimen collection or handling.